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Abstract
Background: Presentation of results of diabetes prevention studies as relative risk reductions and
the use of diagnostic categories instead of metabolic parameters leads to overestimation of effects
on diabetes risk. This survey examines to what extent overestimation of diabetes prevention is
related to overestimation of prevention of late complications.
Methods: Participants of two postgraduate courses in clinical diabetology in Austria (n = 69) and
Germany (n = 31) were presented a questionnaire with 8 items at the beginning of the meetings.
All 100 questionnaires were returned with 92 filled in completely. Participants were asked 1) to
rate the importance of differently framed results of prevention studies and, for comparison, of the
United Kingdom Prospective Diabetes Study (UKPDS), 2) to estimate to what extent late
complications could be prevented by the achieved reductions in diabetes risk or HbA1c values,
respectively.
Results: Prevention of diabetes by 60% was considered important by 84% of participants and 35%
thought that complications could be prevented by ≥ 55%. However, if corresponding HbA1c values
were presented (6.0% versus 6.1%) only 19% rated this effect important, and 12% thought that late
complications could be prevented by ≥ 55%. The difference in HbA1c of 0.9% over 10 years in the
UKPDS was considered important by 75% of participants and 16% thought that complications ('any
diabetes related endpoint') were reduced by ≥ 55% (correct answer <15% by 20% participants).
Conclusion: The novel key message of this study is that the misleading reporting of diabetes
prevention studies results in overestimation of effects on late complications.
Background
Diabetes health care professionals judge the benefit of
preventive interventions substantially higher when
changes in diabetes risk are communicated rather than
related glycaemia parameters. [1]. In a recent study, we
have surveyed participants of three European diabetes
conferences. About 300 physicians and nurse educators
were presented different formats of results of diabetes pre-
vention studies. If results were communicated as a 57%
reduction in diabetes risk about 90% of the diabetes
experts interpreted the effect as important. In contrast, if
the underlying changes of glucose or HbA1c values were
presented, less than 40% rated the results as important
[1]. Transformation of continuous metabolic data into
diagnostic categories interferes with understanding of
study effects.
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Framing of data is a well recognised cause of misconcep-
tions about efficacy of health interventions by physicians
[2-5], patients [2,6], and health care decision makers [7].
This may be particularly relevant to preventive medicine
[8,9]. Our survey has underscored that framing of data is
also relevant for diabetes prevention [1].
However, it is not known why there are such impressive
discrepancies in the ratings of the importance between
changes in glycaemia parameters and risks of diabetes
diagnosis. We hypothesised that diabetes health care pro-
viders may deduce from a 60% reduction in diabetes risk
a comparably high reduction in diabetic late complica-
tions. Therefore, the aim of the present study was to fur-
ther elucidate the framing of data in diabetes prevention
and inferences by health care providers on the prevention
of late complications.
Methods
Participants
The survey samples comprised participants of the 2007
EASD (European Association for the Study of Diabetes)
Postgraduate Course in Evidence-based Clinical Diabetol-
ogy in Austria (n = 69), and participants of the 2007
Annual Meeting of the Schleswig-Holstein Association of
diabetologists in Northern Germany (n = 31). At both
conferences diabetes prevention was a main topic. With
few exceptions participants were certified diabetologists
or other practising physicians with a special interest in
diabetes care. The author was an invited speaker and not
involved in the organisation of the meetings. She asked
the audience for participation in the survey at the very
beginning of the meetings. A questionnaire with 8 items
was presented. In the Austrian meeting the questionnaires
were analysed and descriptive results were presented and
discussed at the end of the meeting. In the German meet-
ing which lasted only half a day results of the Austrian
meeting were presented and discussed. In order to achieve
high participation both surveys were completely anony-
mous. Therefore, no further details on characteristics of
participants were documented. Approval by an ethics
committee was not considered necessary.
Questionnaire
The questionnaire was in German language and based on
the questionnaire which we had piloted and used in our
first survey [1]. Three of the 8 items were related to the pri-
mary outcome ('any diabetes related endpoint') of the
UKPDS [10]. The other five items referred to primary dia-
betes prevention trials [11-14]. Details on the publica-
tions which formed the basis of the questionnaires and
the construction of the first questionnaire have been
described previously [1]. To minimise bias due to the sort-
ing of items three versions of the questionnaire with dif-
ferent orders of items were used (A, B, C). The translated
questionnaire (version A) with an explanation on how
alternative presentations were derived is provided as addi-
tional file 1. Two items (1 and 6) were similar to the pre-
vious survey [1] to allow an estimate on the
reproducibility of results. Identical wording was used in
all items rating effects on diabetes risks or the primary out-
come in the UKPDS: "How important do you consider the
benefit of this intervention?" Participants were asked to
mark their ratings as either "very important", "important",
"not very important" or "not important at all". Wording
on the effects related to prevention of late complications
was also identical for all related items: "What is your esti-
mate? On the long-term late complications could be
reduced by ... " and participants were asked to score one
answer among the following: "more than" 75%, "55 to
75%", "35 to 55%", "15 to 35%", "less than 15%".
Assumptions
Based upon a vast literature on framing of data [2-7] and
the results of our previous survey [1] the following
assumptions were made: 1) Items similar to those of the
first survey (items 1 and 6) achieve comparable ratings as
in the previous study [1]. 2) Effect sizes are rated highest
when presented as relative risk reduction (item 1), fol-
lowed by decreasing importance when results are pre-
sented as HbA1c values (item 3) or natural frequencies
(item 8) for the UKPDS primary endpoint, gain in life
expectancy as estimated for primary prevention studies
(item 5), and of lowest importance when glycosylated
haemoglobin values (HbA1c) are presented for life style
interventions in the primary diabetes prevention studies
(item 6). 3) The extent to which late complications could
be prevented would be rated highest for a 60% reduction
of diabetes risk (item 2), lowest for a change in HbA1c val-
ues from 6.0% to 6.1% (item 7), and in between for the
reduction of HbA1c by almost 1% over 10 years in the
UKPDS (item 4).
Data collection and analysis
Data were analysed using SPSS, version 15.0 for windows.
Comparable to our previous survey [1] only descriptive
data are presented. No statistical comparisons between
subgroups were made.
Results
All 100 distributed questionnaires were returned, and
except 8 all were filled in completely. Predefined assump-
tions were supported by the survey results (Table 1).
Results were comparable across the two survey subpopu-
lations (Table 1 ) and the three versions of the question-
naire (data not shown). 84% of participants considered a
60% reduction in diabetes risk as important (51% as "very
important") but only 19% (2%) when a change in HbA1c
of 0.1% was presented (Figure 1). When the result was
presented as a 60% reduction in diabetes risk 35% of par-BMC Research Notes 2008, 1:90 http://www.biomedcentral.com/1756-0500/1/90
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ticipants expected a reduction of long-term complications
by ≥ 55% but only 12% did so when a decrease in HbA1c
of 0.1% was used (Figure 1). The presentation of expected
life years gained yielded results in between (Table 1).
The difference in HbA1c of 0.9% over 10 years in the
UKPDS was rated important by 75% (by 35% as "very
important"). 16% thought that complications were
reduced by ≥ 55% (43% thought by ≥ 35%, correct
<15%). When the corresponding results of the number of
patients with a primary outcome event were presented (41
versus 46 of 100) only 9% considered this effect as "very
important" (Table 1).
Discussion
The present study supports and extends the findings of
our previous survey [1]. Diabetes experts overestimate the
benefit of preventive interventions when outcomes are
presented as changes in diabetes risk rather than real met-
abolic changes. In addition, the findings further elucidate
the reasoning of physicians confronted with different out-
come descriptions. From a high reduction in diabetes risk
they wrongly infer a high reduction of late complications.
On the other hand, when the corresponding results of
HbA1c values of the same large randomized trials are pre-
sented they expect a much lower reduction of late compli-
cations. Therefore, the original hypothesis of this survey is
supported. Overall, reductions of late complications were
substantially overestimated irrespective of outcome pres-
entation although overestimation was highest when
results were presented as reductions in diabetes risk and
lowest when HbA1c vales were presented supporting the
predefined assumptions of this study.
The diabetes prevention studies included individuals with
elevated fasting and post-load glucose concentrations
who were already at the brink of diabetes [11-13,15,16].
Therefore, minimal differences in fasting plasma glucose
of 0.3 mmol/L or HbA1c values of 0.1% may relate to pro-
nounced differences in proportions of persons with a
diagnosis of diabetes and diabetes risk reductions. In the
Diabetes Prevention Program life style changes reduced
the risk of diabetes by about 50% after 3 years. However,
the corresponding glycaemia changes were modest. After
3 years mean glycosylated haemoglobin was about 6.0%
in the lifestyle intervention group and 6.1% in the control
group as estimated from figure 1 of the publication [13].
Small metabolic differences are magnified by transforma-
tion of continuous data into categorical data [1,17].
Cutoffs for plasma glucose to diagnose diabetes have been
repeatedly challenged as there is no abrupt glycaemic
threshold above which diabetes complications increase
[18]. Therefore, transition from impaired glucose toler-
Table 1: Ratings of diabetes experts of study effects and associated risk reductions of late complications in relation to format of data 
presentation
Rating the benefit of the intervention as Estimates of corresponding reductions of late complications
very
important
important not very
important
not
important at
all
>75% 55–75% 35–55% 15–35% <15%
Diabetes prevention
60% diabetes 
risk reduction 
(item 1 and 2)
35/15
(51%)
19/14
(33%)
8/1
(9%)
6/1
(7%)
7/5
(12%)
14/8
(23%)
9/5
(14%)
11/7
(19%)
25/6
(32%)
HbA1c 6.0% 
versus 6.1% 
(item 6 and 7)
1/1
(2%)
10/7
(17%)
35/15
(51%)
22/8
(30%)
1/1
(2%)
8/2
(10%)
14/5
(19%)
8/5
(13%)
37/18
(56%)
0.288 life 
years gained 
(item 5)
3/3
(6%)
17/9
(27%)
34/15
(50%)
13/4
(17%)
n.a. n.a. n.a. n.a. n.a.
UKPDS
HbA1c 7.0% 
versus 7.9% 
(item 3 and 4)
22/12
(35%)
24/15
(40%)
21/4
(25%)
0/0 2/2
(4%)
7/4
(12%)
20/6
(27%)
22/13
(37%)
13/6
(20%)
41 versus 46 
out of 100 
patients 
(item 8)
5/4
(9%)
36/17
(54%)
25/10
(36%)
1/0
(1%)
n.a. n.a. n.a. n.a. n.a.
Values are numbers of the n = 69 Austrian/n = 31 German samples (percentages of all respondents). UKPDS = United Kingdom Prospective 
Diabetes Study [10]. Numbers may not add up to 100 due to up to 5 missing values. n.a. = not assessedBMC Research Notes 2008, 1:90 http://www.biomedcentral.com/1756-0500/1/90
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Ratings of 100 diabetes experts on the benefit of diabetes prevention interventions on diabetes risk (upper panel) and esti- mates on corresponding reductions of diabetic late complications (lower panel) in relation to the presentation of the results as  either a 60% diabetes risk reduction or the corresponding difference in HbA1c values of 0.1% (6.0% versus 6.1%) Figure 1
Ratings of 100 diabetes experts on the benefit of diabetes prevention interventions on diabetes risk (upper 
panel) and estimates on corresponding reductions of diabetic late complications (lower panel) in relation to 
the presentation of the results as either a 60% diabetes risk reduction or the corresponding difference in 
HbA1c values of 0.1% (6.0% versus 6.1%).BMC Research Notes 2008, 1:90 http://www.biomedcentral.com/1756-0500/1/90
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ance to diabetes may be considered as a change in diag-
nostic labelling rather than change from a health to a
disease state. Cost-effectiveness analyses have estimated
that the Diabetes Prevention Program life style interven-
tion would reduce a high-risk person's 30-year chances of
a serious complication from about 38% to 30% which
relates to an absolute risk reduction of 8% and a relative
risk reduction of 21% [14]. In some of the publications of
the primary prevention studies crucial metabolic data are
not communicated or difficult to extract [1]. The Finish
Diabetes Prevention Study included HbA1c as a secondary
outcome measure [19] but did not report results in the
main publications [11,20]. Neither blood glucose nor
HbA1c values have been reported in the core publication
of the STOP-NIDDM Acarbose prevention study [15].
Despite our previous survey [1] meta-analyses of diabetes
prevention studies continue to be published without
reporting or commenting on metabolic parameters [21].
Incomplete reporting of outcomes within published arti-
cles of randomised trials is common and is associated
with statistical non-significance [22]. Biased reporting
and framing of data by researchers and authors may
enhance misconceptions about treatment effects among
users of study results [1-7].
The present study has limitations. The study population is
a convenience sample and includes only German speak-
ing diabetes experts whereas the previous survey included
both nurses and physicians of international diabetes
meetings. In contrast to our first survey detailed character-
istics of participants were not assessed in the present
study. However, the previous survey also included a well
characterised subgroup of 101 German diabetes experts
who were participants of the 2005 EASD (European Asso-
ciation for the Study of Diabetes) Postgraduate Course in
Evidence-based Clinical Diabetology in Jena, Germany,
an equivalent of the Austrian meeting evaluated in the
present survey. Among the Jena sample of diabetes experts
about 40% worked at primary-care centres, 19% at non-
university hospitals, 27% at university or research institu-
tions, and the rest at other institutions. On average, they
had worked for about 9 years in clinical diabetology and
57% reported to have participated in a course of evidence-
based medicine [1]. Results between both surveys were
comparable on related items. In our previous study a
reduction in diabetes risk of about 60% was rated impor-
tant by 92% and a difference in HbA1c between 6.0% and
6.1% by 18% of participants [1] compared to 84% and
19%, respectively, in the present survey. In both surveys
we have used data from the UKPDS. The UKPDS is a land-
mark study familiar to all diabetologists. Nevertheless, in
our previous survey only 6 out of 299 diabetologists and
diabetes educators could approximately state the frequen-
cies for the primary outcome (41 versus 46 out of 100). Of
those who responded most participants substantially
overestimated the intervention effect. Also, in the present
survey the effect of the intervention was overestimated.
Only 20% gave the correct answer (less than 15%).
Despite these similarities between the two surveys results
of the present study may not be representative for other
countries and other groups of physicians or health care
providers.
Conclusion
This survey provides further insights into the reasoning of
physicians. Diabetes experts overestimate the benefit of
diabetes prevention studies irrespective of outcome pres-
entation. The novel key message of this study is that from
a high reduction of diabetes risk they wrongly infer a high
reduction of late complications. The findings again urge
presentation of study results in a format that can be
understood by health care professionals. Understanding
of prevention studies is fundamental for appropriate allo-
cation of resources.
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